Induction Healthcare Group PLC
(“Induction”, the “Company”, or the “Group”)
Block Listing Six Monthly Return
Induction Healthcare (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| Name of applicant: |
Induction Healthcare Group PLC
LEI: 213800RY96GCZQW5TP19 |
| Name of scheme: |
The Induction Healthcare NTA Share Option Plan |
| Period of return: |
From: |
26/01/2022 |
To: |
26/07/2022 |
| Number and class of securities originally admitted and the date of admission |
3,500,000 ordinary shares on 26 July 2021 |
| Balance of unallotted securities under scheme(s) from initial application: |
3,500,000 |
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
nil |
| Less: Number of securities issued/allotted under scheme(s) during the period: |
396,567 |
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
3,103,433 |
| Contact: |
Alison Talbot, Company Secretary
+44 (0) 3339 398 091 |
|
|
|
|
|
|
|
|
|
|
|
ENQUIRIES
| Induction
James Balmain, Chief Executive Officer
Guy Mitchell, Chief Financial Officer |
Via Walbrook PR Ltd: induction@walbrookpr.com |
|
|
| Singer Capital Markets (Nominated Adviser and Broker) |
+44 (0) 20 7496 3000 |
| Philip Davies / Kailey Aliyar |
|
| |
|
| Walbrook PR Ltd |
induction@walbrookpr.com |
| Paul McManus / Alice Woodings |
Mob: +44(0)7980 541 893 / +44 (0)7407 804 654 |
About Induction – www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face – giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
